TY - T1 - Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma : Long-Term Results of the PRIMA Study SN - / UR - http://hdl.handle.net/10138/310550 T3 - A1 - Bachy, Emmanuel; Seymour, John F.; Feugier, Pierre; Offner, Fritz; Lopez-Guillermo, Armando; Belada, David; Xerri, Luc; Catalano, John V.; Brice, Pauline; Lemonnier, Francois; Martin, Alejandro; Casasnovas, Olivier; Pedersen, Lars M.; Dorvaux, Veronique; Simpson, David; Leppä, Sirpa; Gabarre, Jean; da Silva, Maria G.; Glaisner, Sylvie; Ysebaert, Loic; Vekhoff, Anne; Intragumtornchai, Tanin; Le Gouill, Steven; Lister, Andrew; Estell, Jane A.; Milone, Gustavo; Sonet, Anne; Farhi, Jonathan; Zeuner, Harald; Tilly, Herve; Salles, Gilles A2 - PB - Y1 - 2019 LA - eng AB - PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety. METHODS Patients (> 18 years of age) with previously untreated high-tumor-... VO - IS - SP - OP - KW - NON-HODGKINS-LYMPHOMA; PHASE-III; RESPONSE DURATION; R-CVP; CYCLOPHOSPHAMIDE; THERAPY; CHEMOTHERAPY; VINCRISTINE; PREDNISONE; TRIAL; 3122 Cancers N1 - PP - ER -